Jon Sexton
Pulmonary Disease · Fayetteville, ARNPI 1699703496
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by GSK at 43.6% of the total. Reporting peaked in 2019 at $1,068 and has fallen 78.7% since, to $227 in 2021. That places this record below the midpoint for pulmonary disease clinicians in AR, where the typical reported total is $3,332.
Across 163 payments — averaging $13.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$932
- AstraZeneca$382
- AbbVie$161
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$88
- Circassia Inc.$58
- Insmed, Inc.$56
- plus $463 from 19 others
What the payments were for
- Food & beverage$2,08898%
- Education$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 87 | $932 |
| AstraZeneca | 23 | $382 |
| AbbVie(2 entities) | 11 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $88 |
| Circassia Inc. | 4 | $58 |
| Insmed, Inc. | 3 | $56 |
| CSL Behring | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Covidien LP | 1 | $38 |
| Novartis | 2 | $33 |
| Sanofi | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Shire North American Group Inc | 2 | $25 |
| Genentech USA, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| QOL Medical, LLC | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $17 |
| Merck | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Novo Nordisk | 1 | $12 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Intercept Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,141 in reported general payments places this provider in the 35th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Fayetteville
- Edward JacksonFayetteville$10K
- Barrett BurgerFayetteville$9K
- Ryan JamesFayetteville$7K
- Lindsey BarnesFayetteville$4K
- Gary TempletonFayetteville$2K
- Nathan TobeyFayetteville$2K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.